TNF and irritable bowel syndrome: The use of anti-TNF agents on a larger scale in IBD patients has led to a higher rate of adverse effects, including early-onset local reactions (up to four hours from administration), late-onset local reactions (4 hours to 14 days from administration), opportunistic skin infections, psoriasiform lesions, and a potentially increased risk for skin cancer [1].